VOYAGEUR PHARMACEUTICALS LTD (VM.CA) Stock Price & Overview
TSX-V:VM • CA92918C1014
Current stock price
The current stock price of VM.CA is 0.11 CAD. Today VM.CA is down by -4.35%. In the past month the price decreased by -24.14%. In the past year, price decreased by -31.25%.
VM.CA Key Statistics
- Market Cap
- 19.645M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.02
- Dividend Yield
- N/A
VM.CA Stock Performance
VM.CA Stock Chart
VM.CA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VM.CA. When comparing the yearly performance of all stocks, VM.CA is a bad performer in the overall market: 95.67% of all stocks are doing better.
VM.CA Earnings
VM.CA Forecast & Estimates
VM.CA Financial Highlights
Over the last trailing twelve months VM.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -46.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.97% | ||
| ROE | -216.61% | ||
| Debt/Equity | 0.03 |
VM.CA Ownership
About VM.CA
Company Profile
Voyageur Pharmaceuticals Ltd. engages in exploring and development of barite, iodine, and fullerene Active Pharmaceutical Ingredient (API) minerals. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-05-18. The company focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Company Info
IPO: 2012-05-18
VOYAGEUR PHARMACEUTICALS LTD
Dome Tower 800, 333 7 Ave. S.W.
Calgary ALBERTA T2G 2B3 CA
CEO: Brent Willis
Employees: 0
Phone: 14039235944
VOYAGEUR PHARMACEUTICALS LTD / VM.CA FAQ
What does VM do?
Voyageur Pharmaceuticals Ltd. engages in exploring and development of barite, iodine, and fullerene Active Pharmaceutical Ingredient (API) minerals. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-05-18. The company focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
What is the stock price of VOYAGEUR PHARMACEUTICALS LTD today?
The current stock price of VM.CA is 0.11 CAD. The price decreased by -4.35% in the last trading session.
Does VOYAGEUR PHARMACEUTICALS LTD pay dividends?
VM.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of VM stock?
VM.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for VM stock?
VOYAGEUR PHARMACEUTICALS LTD (VM.CA) currently has 0 employees.